Who owns Callio Therapeutics?

Callio Therapeutics is currently owned by Jeito Capital, through Jeito II, since 2025.

When did Jeito Capital acquire Callio Therapeutics?

Jeito Capital acquired Callio Therapeutics in 2025 (active for 1 year).

Home/Companies/Biotech/Callio Therapeutics

Callio Therapeutics

Biotech·

US·Active·1yr hold

Callio Therapeutics is a healthcare company, headquartered in France.

Entry

2025

Hold

1yr

Status

Active

Est. EV

–

Investor

Jeito Capital

Key facts

HQFrance

SectorHealthcare

Massachusetts-based oncology biotech developing next-generation antibody-drug conjugates; Jeito Capital backed in USD 187M Series A March…Read full notes

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Start free

Already a member? Sign in

More from Jeito II

Other portfolio companies in the same fund.

Augustine Therapeutics

Active

More PE-backed in Biotech

Comparable biotech deals from other GPs.

AdBio PartnersBelgium

Last updated April 2026 · Sourced from public filings